Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats.
We examined the combined effects of elcatonin (ECT) and alendronate (ALN) on bone mass, architecture, and strength in ovariectomized (OVX) rats. Fifty female Sprague Dawley rats, aged 13 weeks, were divided into Sham, OVX, OVX+ECT, OVX+ALN, and OVX+ECT+ALN groups (n = 10). Immediately after ovariectomy, ECT was administered at a dose of 15 units (U)/kg three times a week, and ALN was administered daily at a dose of 2.0 microg/kg, subcutaneously for 12 weeks. The three-dimensional architecture of the bone in the distal femoral metaphysis was analyzed using a microfocus X-ray computed tomography system (microCT), and bone strength was measured using a material-testing machine. Trabecular bone volume (BV/TV) and number (Tb.N) were significantly greater in the OVX+ECT and OVX+ALN groups than in the OVX group. In the OVX+ECT+ALN group, BV/TV and Tb.N were significantly greater when compared with those in the OVX+ECT and OVX+ALN groups. Trabecular thickness (Tb.Th) was significantly greater in the OVX+ECT+ALN group than in the OVX+ALN group. With regard to bone strength, the compression strength in the femoral metaphysis was significantly lower in the OVX group than in the Sham group. The reduction of compression strength was slightly lower in the OVX+ECT and OVX+ALN groups. In the OVX+ECT+ALN group, the compression strength in the femoral metaphysis significantly increased when compared with the OVX and OVX+ECT groups. These results suggest that the combined treatment of ECT and ALN does not alter the individual effects of each drug and that it exerts an additive effect on trabecular architecture and bone strength in OVX rats.
Ogawa
Koko
K
First Laboratory for Pharmacology, Institute for Life Science Research, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni 410-2321, Japan. ogawa.kb@asahi-kasei.co.jp
Hori
Masayuki
M
Takao
Ryoko
R
Sakurada
Toyozo
T
D019386:Alendronate / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D002116:Calcitonin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D019245:Compressive Strength; D004359:Drug Therapy, Combination; D005260:Female; D005269:Femur / Q000187:drug effects / Q000473:pathology; D006801:Humans; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods
D002116:Calcitonin; C012755:elcatonin; D019386:Alendronate